An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Geron (Nasdaq: GERN) will announce its first quarter 2024 financial results and business highlights on May 2, 2024. The company will host a conference call to discuss the results and highlights at 8:00 a.m. ET the same day.
Geron (Nasdaq: GERN) annuncerà i risultati finanziari del primo trimestre del 2024 e gli highlights aziendali il 2 maggio 2024. La società organizzerà una conferenza telefonica per discutere dei risultati e degli highlights alle 8:00 del mattino, ora orientale, dello stesso giorno.
Geron (Nasdaq: GERN) anunciará sus resultados financieros del primer trimestre de 2024 y los puntos destacados de la empresa el 2 de mayo de 2024. La compañía llevará a cabo una conferencia telefónica para discutir los resultados y los puntos destacados a las 8:00 a.m. ET ese mismo día.
Geron (나스닥: GERN)은 2024년 1분기 재무 결과 및 사업 하이라이트를 2024년 5월 2일에 발표할 예정입니다. 회사는 같은 날 오전 8시(동부 표준시)에 결과와 하이라이트를 논의하기 위한 전화 회의를 개최할 것입니다.
Geron (Nasdaq : GERN) annoncera ses résultats financiers pour le premier trimestre 2024 et les points forts de l'entreprise le 2 mai 2024. La société organisera une conférence téléphonique pour discuter des résultats et des points forts à 8h00 HE le même jour.
Geron (Nasdaq: GERN) wird am 2. Mai 2024 seine Finanzergebnisse für das erste Quartal 2024 und Geschäftshighlights bekannt geben. Das Unternehmen wird am selben Tag um 8:00 Uhr ET eine Telefonkonferenz veranstalten, um die Ergebnisse und Highlights zu diskutieren.
Positive
None.
Negative
None.
FOSTER CITY, Calif.--(BUSINESS WIRE)--
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2024 financial results and business highlights before the market opens on Thursday, May 2, 2024 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. ET the same day.
A live webcast of the conference call and related presentation will be available on the Company’s website at www.geron.com/investors/events. An archive of the webcast will be available on the Company’s website for 30 days.
Geron is a late-stage clinical biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Our first-in-class investigational telomerase inhibitor, imetelstat, harnesses Nobel Prize-winning science in a treatment that may alter the underlying drivers of disease. The New Drug Application (NDA) for imetelstat for the treatment of transfusion dependent anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) who have failed to respond or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs), based on the results from the Phase 3 IMerge clinical trial, is currently under review by the United States Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 16, 2024. In addition, an MAA is under review in the European Union for the same proposed indication. Furthermore, Geron currently has an ongoing pivotal Phase 3 clinical trial evaluating imetelstat in relapsed/refractory myelofibrosis (R/R MF). To learn more, visit www.geron.com or follow us on LinkedIn.
we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.
